-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvation Bio Presents IBTROZI Launch Update, Reports $27.5 Million in Q3 U.S. Net Product Revenue

PUBT·11/04/2026 23:03:54
Listen to the news
Nuvation Bio Presents IBTROZI Launch Update, Reports $27.5 Million in Q3 U.S. Net Product Revenue
  • Nuvation Bio expects its approximately $663 million cash balance to fund a path to profitability without additional financing.
  • IBTROZI U.S. net product revenue reached $27.5 million in the third quarter of 2026, up from $23.2 million in the second quarter.
  • New first-line patient starts captured more than 60% market share as of September 30, 2026; total starts since launch reached approximately 920.
  • Safusidenib’s pivotal SIGMA study is enrolling patients with high-risk astrocytoma; a phase 3 study in grade 2 glioma is being initiated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.